AltraVax acquires vaccine advancement technology package from Maxygen AltraVax

AltraVax acquires vaccine advancement technology package from Maxygen AltraVax, Inc., a new, privately-held biopharmaceutical organization, has acquired a vaccine development technology bundle from Maxygen, Inc more info . that gives AltraVax a special license to develop vaccines for infectious illnesses and is usually targeting influenza, a treatment for hepatitis B and HIV. The technology can considerably compress vaccine advancement timelines, resulting in new vaccine possibilities that have the potential to improve and protect human wellness globally. Related StoriesBasic study for developing toxoplasma vaccine underwayResearch provides qualified prospects for new ways of develop HIV vaccineKey component of MRSA vaccine puzzle unearthedArthur Ventures Growth Fund, LLC is the lead trader in AltraVax.

36 hours

Choice vaccine to Dryvax for smallpox Not everybody could be vaccinated against smallpox using the current FDA-approved vaccine safely. ‘There are limitations to the current vaccine,’ stated Sharon Frey, M.D., from Saint Louis University's Center for Vaccine Development. So, for example, if you are HIV-positive or undergoing chemotherapy for tumor, you shouldn't receive the currently licensed vaccine.’ Related StoriesSinovac Dalian receives acceptance to start human clinical trials of varicella vaccine candidateKey part of MRSA vaccine puzzle unearthedAnalyzing potential TB vaccine Dr. Frey said this study vaccine, referred to as MVA-BN and offered through Bavarian Nordic, differs than additional vaccines that are now available. Just like the current vaccines, the scholarly research vaccine is normally a live-virus vaccine made from vaccinia virus, but this study vaccine contains a more ‘attenuated,’ or weakened, type of the virus.

Other entries from category "immunology":

Random entries